Prurisol is done. It has been adequately tested and removed from the company website.
Management has now put all focus on the two remaining drugs in the pipeline and is working to secure working capital. Hopefully most will come from the potential Brilacidin partner we were told about last year, as it would be by far the cheapest funding for existing shareholders.
If we don't get the partnership, it will be interesting to see if the MFO offers a second equity deal. One thing is for sure, our capital would be enormously expensive regardless.
Let's see what January brings. We will hear one way or the other soon. GLTA :)
News 
Market Data 
Discover 
